Publication Type:

Journal Article


Int J Biol Macromol, Volume 110, p.133-139 (2018)


amphotericin B, Animals, Candida glabrata, Candidiasis, chitosan, Drug Delivery Systems, Macrophages, Mice, Nanoparticles, RAW 264.7 Cells


<p>The current study assesses the potential of functionalised chitosan nanoparticles (CNPs) for proficient macrophage delivery of amphotericin B (AmpB) for the management of Candida glabrata fungemia. Chitosan was functionalised by the method of sulfation by using chlorosulfonic acid and the developed compound was confirmed by FTIR, H NMR and degree of sulfation and CHNS analysis. Amphotericin B encapsulated sulfated chitosan (AmpB-SCNPs), when characterized showed a hydrodynamic diameter of 310 ± 14 nm and zeta potential of 41.5 ± 2 mV. The safety of AmpB-SCNPs was established by the alamar cytotoxicity assay in nanoparticle treated macrophages following 24 h incubation. The AmpB-SCNPs showed a significant increase in the reduction of C. glabrata in comparison with the bare AmpB and AmpB-CNPs (55.2 and 42.7 vs 11.12 cfu/ml) indicating that AmpB-SCNPs could be a promising carrier for specific delivery of AmpB to macrophages for effective treatment of Candida glabrata fungemia.</p>

Cite this Research Publication

M. Sandhya, V, A., K, S. Maneesha, Raja, B., R, J., and S, S., “Amphotericin B loaded sulfonated chitosan nanoparticles for targeting macrophages to treat intracellular Candida glabrata infections.”, Int J Biol Macromol, vol. 110, pp. 133-139, 2018.